Etude des besoins et pratiques du personnel scientifique de l'ISDC au sein de sa bibliothèque de recherche

Ce travail a pour objectif de comprendre les attentes de l’équipe scientifique de l’Institut suisse de droit comparé (ci-après ISDC) envers sa bibliothèque. Il s’agit de dresser un état des lieux des pratiques actuelles de ce type d’usagers via des entretiens individuels et un questionnaire d’enquête adressé à l’ensemble de l’équipe. La question de départ a été de savoir quels services pourraient répondre de manière la plus optimale aux besoins de ce public, besoins qu’il a fallu identifier. Il a donc également été question de comprendre les relations qu’entretiennent les deux équipes (bibliothèque et équipe scientifique) en matière de partage d’information et de collaboration. Afin de mieux inscrire cette étude dans son contexte, une présentation de l’ISDC se trouve au début de ce travail, viennent ensuite les entretiens individuels et le ques- tionnaire d’enquête

Aspects physico-chimiques des milieux utilisés pour la production d'embryons in vitro chez les mammifères

LYON1-BU Santé (693882101) / SudocSudocFranceF

Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial.

International audienceOBJECTIVES: The ANRS-112 INTERPRIM trial assessed whether fixed-cycles of antiretroviral treatment interruption (ART-STI) combined or not with pegylated interferon alpha-2b (peg-IFN) could lower viral load and achieve a healthier immune system in patients diagnosed during primary HIV-1-infection (PHI). DESIGN AND METHODS: Patients were randomized to receive either continuous ART (cART) during 72 weeks, or cART during 36 weeks followed by three ART-STIs, or the same ART-STIs associated with peg-IFN during the first 14 weeks and each interruption (ART-STI-IFN). Treatment was stopped at week 72. Final evaluation was based on plasma HIV-RNA level 6 months after the last treatment interruption. RESULTS: Eighty-seven percent of patients achieved undetectable HIV-RNA at week 32, with no deleterious impact of sequential treatment interruptions (STIs). Viral rebounds during interruptions were lower in the ART-STI-IFN than in the ART-STI group and during the second and third interruptions compared with the first one. However, HIV-RNA levels, CD4 T-cell counts and CD4 T/CD8 T ratios were similar between groups after the 6-month interruption, with a persistent effect on CD4 T cells and total cell-associated HIV-DNA levels. Predictive factors of virological outcome were HIV-RNA and HIV-DNA levels at PHI and HIV-DNA levels at treatment interruption. HIV-specific responses did not differ between strategies and were not associated with outcome. Forty-eight percent of patients experienced treatment resumption during long-term follow-up without difference between groups. CONCLUSION: When initiated during PHI, STIs associated or not with IFN did not result in a different outcome as compared to cART. All regimens showed a high response rate and a sustained immunological benefit after cessation